Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26209859 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nabanita Mukherjee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-2, Antineoplastic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.
Abstract (Originalsprache)
The BCL2 family of proteins plays a pivotal role in regulating apoptosis and cellular homeostasis, making them critical therapeutic targets in cancer and other diseases characterized by pathological cell survival. BH3 mimetics, small molecules that selectively inhibit anti-apoptotic BCL2 family members, have achieved significant clinical success, particularly in hematologic malignancies. However, several challenges remain, including resistance mechanisms, toxicity (such as MCL1 inhibitor-associated cardiotoxicity), and the intricate balance between apoptotic and non-apoptotic functions. This review provides a comprehensive overview of BCL2 family biology, the development and clinical application and outcomes of BH3 mimetics, and the emerging resistance mechanism known as double-bolt locking. We also examine strategies to overcome resistance, including combination therapies and immunomodulatory approaches. Beyond oncology, we highlight the expanding therapeutic potential of BH3 mimetics in autoimmune, fibrotic, and infectious diseases, as well as regenerative and anti-aging medicine. Finally, we discuss predictive biomarkers and tissue-specific responses that inform precision therapy. Together, these insights underscore the promise of BH3 mimetics and the need for continued multidisciplinary research to optimize their clinical impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Gates Institute, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Rocky Mountain Regional VA Medical Center, Aurora, CO 80045, USA.
ORCID-Profile: Yiqun G Shellman
Förderung
- BLRD VA
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health
- Department of Veterans Affairs, Biomedical Laboratory Research and Development
Zitieren
APA
Mukherjee, N., Sheetz, J., & Shellman, Y. G. (2025). Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26209859
Vancouver
Mukherjee N, Sheetz J, Shellman YG. Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26209859
BibTeX
@article{Mukherjee2025,
author = {Mukherjee, Nabanita and Sheetz, James and Shellman, Yiqun G},
title = {Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26209859}
}
EUVIMED